$5.75 Billion is the total value of Avoro Capital Advisors LLC's 46 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 46.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $159,288,000 | -47.1% | 790,000 | -43.6% | 2.77% | -46.7% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $62,342,000 | -19.7% | 1,825,000 | -22.7% | 1.08% | -19.2% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $59,552,000 | -7.7% | 2,441,658 | -2.3% | 1.04% | -7.0% |
| ISEE | Sell | IVERIC BIO INC | $40,542,000 | -9.5% | 6,425,000 | -11.4% | 0.70% | -8.9% |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $29,929,000 | -44.3% | 935,000 | -38.7% | 0.52% | -43.8% |
| ADVM | Sell | ADVERUM BIOTECHNOLOGIES INC | $24,325,000 | -69.2% | 6,950,000 | -13.1% | 0.42% | -68.9% |
| MRUS | Sell | MERUS N V | $13,906,000 | +0.1% | 660,000 | -0.8% | 0.24% | +0.8% |
| ADAP | Sell | ADAPTIMMUNE THERAPEUTICS PLCsponsored adr | $8,624,000 | -54.3% | 2,024,400 | -43.0% | 0.15% | -54.0% |
| GLPG | Exit | GALAPAGOS NVsponsored adr | $0 | – | -3,100 | -100.0% | -0.00% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -555,000 | -100.0% | -0.10% | – |
| RACA | Exit | THERAPEUTICS ACQUISITION CORP | $0 | – | -1,000,000 | -100.0% | -0.18% | – |
| BDTX | Exit | BLACK DIAMOND THERAPEUTICS INC | $0 | – | -440,000 | -100.0% | -0.18% | – |
| RLAY | Exit | RELAY THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -0.30% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -1,249,000 | -100.0% | -0.54% | – |
| Exit | ASCENDIS PHARMAsponsored adr | $0 | – | -1,900,000 | -100.0% | -4.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.